- Discovery of Novel UDP- N-Acetylglucosamine Acyltransferase (LpxA) Inhibitors with Activity against Pseudomonas aeruginosa
-
This study describes a novel series of UDP-N-acetylglucosamine acyltransferase (LpxA) inhibitors that was identified through affinity-mediated selection from a DNA-encoded compound library. The original hit was a selective inhibitor of Pseudomonas aeruginosa LpxA with no activity against Escherichia coli LpxA. The biochemical potency of the series was optimized through an X-ray crystallography-supported medicinal chemistry program, resulting in compounds with nanomolar activity against P. aeruginosa LpxA (best half-maximal inhibitory concentration (IC50) 20 μM and MIC > 128 μg/mL). The mode of action of analogues was confirmed through genetic analyses. As expected, compounds were active against multidrug-resistant isolates. Further optimization of pharmacokinetics is needed before efficacy studies in mouse infection models can be attempted. To our knowledge, this is the first reported LpxA inhibitor series with selective activity against P. aeruginosa.
- Andersen, Ole A.,Barbeau, Olivier R.,Barker, John,Cain, Ricky,Centrella, Paolo A.,Clark, Matthew A.,Compper, Christel,Corbett, David,Cuozzo, John W.,Dejob, Magali,Dejonge, Boudewijn L. M.,Deng, Boer,Dickie, Anthony P.,Dorali, Alain,Etheridge, Donnya,Evans, Sian,Faulkner, Adele,Gadouleau, Elise,Gorman, Timothy,Haase, Denes,Holbrow-Wilshaw, Maisie,Hunt, Avery,Keefe, Anthony D.,Krulle, Thomas,Li, Xianfu,Lumley, Christopher,Mertins, Barbara,Napier, Spencer,Odedra, Rajesh,Papadopoulos, Kostas,Parkes, Alastair L.,Roumpelakis, Vasileios,Ryan, M. Dominic,Sanzone, Angelo,Sigel, Eric A.,Southey, Michelle,Soutter, Holly T.,Spear, Kate,Stein, Daniel B.,Thommes, Pia,Trimby, Emily,Troast, Dawn M.,Williams, Jennifer,Zahn, Michael,Zhang, Ying
-
p. 14377 - 14425
(2021/10/25)
-
- Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists
-
Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50 = 62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.
- Wang, Xuekun,Zhao, Tianxiao,Yang, Baowei,Li, Zheng,Cui, Jian,Dai, Yuxuan,Qiu, Qianqian,Qiang, Hao,Huang, Wenlong,Qian, Hai
-
p. 132 - 140
(2015/02/18)
-
- Novel compounds, their preparation and use
-
Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be u
- -
-
Page/Page column 33
(2010/02/11)
-